This Company's New Approach Could Slash Gilead's Profit From HIV Drugs

Jason Hawthorne, The Motley Fool
·5-min read
This Company's New Approach Could Slash Gilead's Profit From HIV Drugs
This Company's New Approach Could Slash Gilead's Profit From HIV Drugs

Although the "cheaper" part of that scenario doesn't apply yet, gene editing could be getting ready to decimate the profits of Gilead Sciences (NASDAQ: GILD) and its most profitable drugs. A small private biotech has data showing that its use of CRISPR-Cas9 gene editing could potentially eliminate the need for patients -- and those at risk -- to take HIV drugs for the rest of their lives. If the clinical trials succeed, Gilead's shareholders could be in big trouble.